• print
  • mail
  • Home
  • Media
  • Featured Content
  • Update to U.S. Prescribing Information for Aranesp® and EPOGEN®

  • Overview
  • Fact Sheets
  • Featured Content
  • News Releases
  • Our Perspective
  • Social Media
  • Media Contacts
  • In the News
  • Virtual Press Kits
Update to U.S. Prescribing Information for Aranesp® and EPOGEN®

Amgen is committed to the highest standards of patient safety.

  • Amgen Announces Update to U.S. Prescribing Information for Aranesp® (darbepoetin alfa) and EPOGEN® (Epoetin alfa)
  • Amgen’s Statement on Safety of Aranesp® (darbepoetin alfa) and EPOGEN® (Epoetin alfa)
  • UPDATED: Letter to Healthcare Professionals
  • UPDATED: Prescribing information for Aranesp® (darbepoetin alfa)
  • UPDATED: Prescribing information for EPOGEN® (Epoetin alfa)

 


footer